 INDIANAPOLIS, Aug. 9, 2021 PRNewswire -- Sexton Biotechnologies, a provider of novel manufacturing solutions for the cell and gene therapy CGT industry, today announced that it has entered into a definitive agreement whereby BioLife Solutions NASDAQ: BLFS will acquire all outstanding shares of the company in a deal worth a total value of 30 million. During the past two years, Sexton has worked to provide end-to-end solutions for emerging cell and gene therapy manufacturers. 